… Semi-synthetic second-generation TC, including minocycline and doxycycline, are currently
… Recently, in an animal model of PD, we showed that doxycycline, when administered at a …

… tool for mental disorders. Minocycline (MINO) and doxycycline (DOXY) are semisynthetic …
Also, in a mouse model of Huntington disease, MINO could inhibit the cytoplasmatic release …

… minocycline inhibits caspase-1 and caspase-3 expression, delaying mortality in the animal
model of Huntington's disease [… Doxycycline and minocycline for the management of acne: a …

… Although it is well established that neuroinflammation is a pathogenic mechanism observed
in HD patients, the N171-82Q HD mouse model used in this study may not be the ideal …

… b In an absence of doxycycline, rtTA fails to bind the tet-promoter. c … disease progression).
Co-treatment of the transgenic mouse model with the microglial activation inhibitor minocycline …

… In our study, we demonstrated that the protective effect of doxycycline in a model treated
with MPP + is associated with neurotrophic activity, which suggests a potential for axonal …

… NO sufficient to cause cartilage damage (48). In cultures of cartilage cuts, doxycycline or
minocycline … In a murine model of dextran sodium sulfate-induced acute colitis, treatment with …

… is not entirely understood, we herein investigated the role of immune activation in HD using
the R6/2 transgenic (Tg) HD model … However, some studies have reported that minocycline …

… , as shown in mouse models of Huntington disease 12 and amyotrophic lateral sclerosis (ALS).
Hereby, minocycline acts not only by … Doxycycline, which belongs to the same group as …

… Although minocycline has been in clinical use since 1971, its … Preclinically minocycline has
been shown to have various … This might make YACNSG a good model to study the efficacy …